Symtomax has created its very own CBD oral tab as a novel and innovative delivery form for cannabinoids.
Over the last few years the global market for cannabidiol (CBD) has expanded rapidly with growing demand for CBD products expected to continue through 2022 – transforming this market into a mega industry of its own.
According to the latest research by the Global Wellness Institute (GWI), the worldwide wellness market grew 12.9% from $3.72tn in 2017 to a $4.2tn (~€3.5tn) in 2018.
Today the European market for CBD is worth approximately €450m accounting for approximately 31% of the global CBD oil market share, second only to North America.
However, momentum is gathering quickly as more people recognise the substantial potential of products enriched with cannabinoids. As a result, EU projections are estimating that the market to grow to at least €1.5bn by 2023.
The potential for CBD and other cannabinoids is in its infancy with numerous clinical trials and studies underway to understand how cannabinoids offer symptomatic relief to common ailments including inflammation, pain, insomnia and anxiety.
Part of CBD’s growing mainstream popularity appears to stem from it being ‘non psychoactive,’ meaning that consumers can reap health benefits without impairment or mind altering effects.
Today the European market for CBD is approximately €450 million accounting for approximately 31% of global CBD oil market share, second only to North America. However, momentum is gathering quickly as more people recognise the potential of cannabinoid enriched products. As a result, EU projections are estimating the market to grow to at least €1.5 billion by 2023.
Relief at last! Oral tabs
As Europe familiarises itself with CBD and its potential health benefits, a wide range of opportunities are starting to materialise for cannabis companies. Symtomax, based in Portugal is the largest cultivation facility in Europe and leading the industry with the introduction of a unique delivery system, branded the Oral Tab.
The Oral Tab is built on a thin film which adheres to the inside of the cheek. Proprietary technology allows the release of cannabinoids from multiple layers of the tab, each of which has a predetermined time interval. This means that the delivery method has the ability to cater to patients seeking either an instant dose of cannabinoids or those requiring a timed release profile over a few hours which is a challenge when using more traditional preparations.